ACRS · Aclaris Therapeutics, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $2.00M | - | $3.30M | $1.78M | $1.46M | - | $4.35M | $2.77M | $2.40M | - |
| Cost of Revenue | $395.0K | - | $538.0K | $515.0K | $506.0K | - | $654.0K | $624.0K | $809.0K | - |
| Gross Profit | $1.60M | - | $2.76M | $1.26M | $949.0K | - | $3.69M | $2.14M | $1.59M | - |
| R&D | $15.66M | - | $13.03M | $11.45M | $11.58M | - | $5.96M | $8.76M | $9.85M | - |
| SG&A | $6.74M | - | $4.87M | $5.39M | $6.14M | - | $5.65M | $4.75M | $6.84M | - |
| Total Operating Expenses | $24.19M | - | $20.45M | $20.18M | $19.54M | - | $14.82M | $15.62M | $21.33M | - |
| D&A | $102.0K | - | $100.0K | $100.0K | $128.0K | - | $200.0K | $200.0K | $243.0K | - |
| Operating Income | ($22.19M) | - | ($17.15M) | ($18.41M) | ($18.08M) | - | ($10.47M) | ($12.85M) | ($18.93M) | - |
| Interest Expense | - | - | - | - | - | - | - | - | - | - |
| Income Tax | - | - | - | - | - | - | - | - | - | - |
| Net Income | ($19.82M) | - | ($14.61M) | ($15.43M) | ($15.09M) | - | ($7.59M) | ($10.99M) | ($16.94M) | - |
| EPS - Basic | ($0.15) | - | ($0.12) | ($0.13) | ($0.12) | - | ($0.11) | ($0.15) | ($0.24) | - |
| EPS - Diluted | ($0.15) | - | ($0.12) | ($0.13) | ($0.12) | - | ($0.11) | ($0.15) | ($0.24) | - |
Balance Sheet
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $28.66M | $19.96M | $25.26M | $25.40M | $30.36M | $24.57M | $47.65M | $22.83M | $35.84M | $39.88M |
| Accounts Receivable | - | - | - | $194.0K | $250.0K | $318.0K | $343.0K | $325.0K | $373.0K | $298.0K |
| Inventory | - | - | - | - | - | - | - | - | - | - |
| Accounts Payable | $14.73M | $13.16M | $9.19M | $8.80M | $6.35M | $4.69M | $7.66M | $7.27M | $10.81M | $8.88M |
| Current Assets | $110.23M | $96.32M | $100.59M | $104.20M | $108.79M | $125.95M | $132.33M | $117.64M | $135.34M | $128.86M |
| Total Assets | $198.72M | $160.46M | $175.53M | $189.15M | $198.09M | $220.33M | $182.39M | $161.07M | $174.06M | $197.41M |
| Current Liabilities | $27.37M | $28.64M | $25.63M | $26.84M | $21.51M | $31.60M | $18.82M | $15.68M | $20.08M | $30.95M |
| Long-term Debt | - | - | - | - | - | - | - | - | - | - |
| Total Liabilities | $55.07M | $57.38M | $55.43M | $57.41M | $54.03M | $64.77M | $52.24M | $27.25M | $32.05M | $40.23M |
| Stockholders' Equity | $143.65M | $103.08M | $120.10M | $131.74M | $144.07M | $155.55M | $130.15M | $133.82M | $142.01M | $157.18M |
| Retained Earnings | ($987.61M) | ($967.78M) | ($947.99M) | ($933.38M) | ($917.95M) | ($902.86M) | ($806.31M) | ($798.72M) | ($787.74M) | ($770.80M) |
Cash Flow
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | ($18.15M) | - | - | - | ($13.06M) | - | - | - | ($20.82M) | - |
| Investing Cash Flow | ($30.93M) | - | - | - | $19.12M | - | - | - | $16.83M | - |
| Financing Cash Flow | $57.78M | - | - | - | ($275.0K) | - | - | - | ($55.0K) | - |
| CapEx | $13.0K | - | - | - | $43.0K | - | - | - | $135.0K | - |
| Free Cash Flow | ($18.16M) | - | - | - | ($13.10M) | - | - | - | ($20.95M) | - |
Ratios
| Metric | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | 80.2% | - | 83.7% | 71.0% | 65.2% | - | 85.0% | 77.4% | 66.3% | - |
| Operating margin | -1111.8% | - | -519.8% | -1035.9% | -1242.9% | - | -240.9% | -464.7% | -789.4% | - |
| EBITDA margin | -1106.7% | - | -516.8% | -1030.3% | -1234.1% | - | -236.3% | -457.5% | -779.3% | - |
| Net margin | -993.2% | - | -443.0% | -868.3% | -1036.8% | - | -174.6% | -397.2% | -706.5% | - |
| Free cash flow margin | -909.9% | - | - | - | -900.3% | - | - | - | -873.6% | - |
| FCF / Net income | 0.92 | - | - | - | 0.87 | - | - | - | 1.24 | - |
| R&D / Revenue | 784.4% | - | 394.9% | 644.3% | 796.2% | - | 137.0% | 316.7% | 410.6% | - |
| SG&A / Revenue | 337.8% | - | 147.7% | 303.1% | 421.9% | - | 130.1% | 171.8% | 285.4% | - |
| Effective tax rate | - | - | - | - | - | - | - | - | - | - |
| Return on assets | -10.0% | - | -8.3% | -8.2% | -7.6% | - | -4.2% | -6.8% | -9.7% | - |
| Return on equity | -13.8% | - | -12.2% | -11.7% | -10.5% | - | -5.8% | -8.2% | -11.9% | - |
| Return on invested capital | - | - | - | - | - | - | - | - | - | - |
| Liquidity | ||||||||||
| Current ratio | 4.03 | 3.36 | 3.92 | 3.88 | 5.06 | 3.99 | 7.03 | 7.50 | 6.74 | 4.16 |
| Quick ratio | 4.03 | 3.36 | 3.92 | 3.88 | 5.06 | 3.99 | 7.03 | 7.50 | 6.74 | 4.16 |
| Cash ratio | 1.05 | 0.70 | 0.99 | 0.95 | 1.41 | 0.78 | 2.53 | 1.46 | 1.78 | 1.29 |
| Leverage | ||||||||||
| Debt / Equity | - | - | - | - | - | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest coverage | - | - | - | - | - | - | - | - | - | - |
| Equity multiplier | 1.38 | 1.56 | 1.46 | 1.44 | 1.38 | 1.42 | 1.40 | 1.20 | 1.23 | 1.26 |
| Liabilities / Assets | 0.28 | 0.36 | 0.32 | 0.30 | 0.27 | 0.29 | 0.29 | 0.17 | 0.18 | 0.20 |
| Efficiency | ||||||||||
| Asset turnover | 0.01 | - | 0.02 | 0.01 | 0.01 | - | 0.02 | 0.02 | 0.01 | - |
| Inventory turnover | - | - | - | - | - | - | - | - | - | - |
| Days sales outstanding | - | - | - | 40d | 63d | - | 29d | 43d | 57d | - |
| Days inventory outstanding | - | - | - | - | - | - | - | - | - | - |
| Days payable outstanding | 13612d | - | 6233d | 6235d | 4583d | - | 4276d | 4252d | 4877d | - |
| Cash conversion cycle | - | - | - | - | - | - | - | - | - | - |
| Valuation | ||||||||||
| P / E | - | - | - | - | - | - | - | - | - | - |
| P / B | 3.4x | - | 1.9x | 1.3x | 1.3x | - | 0.6x | 0.6x | 0.6x | - |
| P / S | 242.0x | - | 70.6x | 98.0x | 128.7x | - | 18.9x | 28.4x | 36.8x | - |
| EV / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | 37.2% | - | -24.1% | -35.8% | -39.3% | - | -53.2% | 48.0% | -5.1% | - |
| Revenue CAGR (3y) | -7.6% | - | -44.2% | 5.2% | 0.0% | - | 37.9% | 14.9% | 10.5% | - |
| Revenue CAGR (5y) | 2.4% | - | 17.9% | -2.8% | 0.7% | - | 34.6% | -14.0% | -13.8% | - |
| Gross profit growth (YoY) | 68.7% | - | -25.2% | -41.1% | -40.3% | - | -56.2% | 159.0% | -7.6% | - |
| Operating income growth (YoY) | -22.7% | - | -63.8% | -43.2% | 4.5% | - | 66.8% | 59.6% | 36.7% | - |
| Net income growth (YoY) | -31.4% | - | -92.6% | -40.4% | 11.0% | - | 74.1% | 62.8% | 39.8% | - |
| EPS growth (YoY) | -25.0% | - | -9.1% | 13.3% | 50.0% | - | 73.2% | 64.3% | 42.9% | - |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | -38.6% | - | - | - | 37.5% | - | - | - | 22.1% | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | -0.3% | -33.7% | -7.7% | -1.6% | 1.4% | -1.0% | -16.7% | -25.6% | -19.7% | -20.5% |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2025-12-31.
Business segments
$7.83M totalSingle Reportable Segment$7.83M · 100.0%
Product / service
$15.65M totalDermatology Therapeutics Segment$5.95M · 38.0%
License And Service$5.95M · 38.0%
Contract Research Segment$1.87M · 12.0%
Laboratory Research Revenue$1.87M · 12.0%
Peer comparison
Same SIC group: Pharmaceutical Preparations
Comparing Aclaris Therapeutics against the 5 most active filers in the same SIC group.